Ulcer Drug Research Articles

A Clinical and Socio-medical Investigation of Patients 5 Years after Surgical Treatment for Duodenal Ulcer

Within the framework of the Aarhus County Vagotomy Trial a socio-medical interview investigation was performed. Ninety-one patients were asked to participate. Half of the patients had an ulcer history of more than 15 years. One fifth had experienced preoperative complications. Thirty-nine per cent of the patients showed changes in social activity according to Patrick's grading. Within work and leisure time significant improvements had taken place. Most of the patients with paid work were characterized by a high degree of satisfaction, conscientiousness, and stability at work. Symptoms indicating psychological impairment were commoner among the patients than in the background population. No accumulation of tobacco or alcohol abuse was found. The consumption of medicine was rather high. During the period of observation a decrease in the consumption of ulcer drugs, but not in other drugs, was noted. The frequency of sick days was rather high. The rate of consultations at the general practitioner did not differ from what would be expected. It is suggested that surgical cure of an ulcer only has some impact on the total life situation of the patients and that non-specific psychological symptoms in some patients may invalidate the overall result of treatment.

New Isoprene Chemicals

Recent progress of industrially important isoprene chemicals is reviewed.Many various chemicals were synthesized by using isoprene as a starting material. Aroma chemicals, medicinal chemicals, agrochemicals, and their intermediates, for example, new type aroma chemicals having woody note, pheromones, drugs for ulcer, vitamines, and so on, and new synthesizing routes for those isoprene derived chemicals are briefly described.

New drugs for peptic ulcer

New drugs for peptic ulcer

New drugs for peptic ulcer.

New drugs for peptic ulcer.

New drugs for peptic ulcer.

New drugs for peptic ulcer.

Medical News

<h3>Side effects of cimetidine use coming under scrutiny</h3> In a cruel twist of fate for the manufacturers of the peptic ulcer drug cimetidine, a recent federal hearing convened for the purpose of expanding the official clinical indications for cimetidine use to include long-term maintenance therapy was transformed into a veiled indictment of the agent. The hearing was conducted by the Food and Drug Administration's Gastrointestinal Drugs Advisory Committee at the request of Smith Kline &amp; French Laboratories, the principal manufacturers of cimetidine. Unfortunately for the company, recent articles in<i>The Lancet</i>(1:1005-1006, 1979), suggesting a link between cimetidine and gastric cancer, and in<i>The New England Journal of Medicine</i>(300:1012-1015, 1979), showing reductions in sperm counts after cimetidine therapy, altered the mood of the hearing from cooperation to interrogation. Nevertheless, the committee agreed that cimetidine is indicated in the long-term treatment of the most serious cases of duodenal ulcer.

Cimetidine for duodenal ulceration in patients undergoing haemodialysis.

Peptic ulcer is a common problem in advanced renal failure, but most drugs for ulcers are hazardous in this condition. In a small open study cimetidine was given to nine patients with acid hypersecretion and endoscopically diagnosed duodenal ulceration who were undergoing haemodialysis. The patients obtained good pain relief and suffered no serious side effects. Both basal and stimulated acid output fell considerably and the plasma gastrin response to food increased during treatment. Two patients with recurrent vomiting during haemodialysis had a striking response to cimetidine, which suggested that such vomiting may be acid-mediated in some patients. These preliminary results suggest that cimetidine may prove to be an advance in the management of peptic ulcer in uraemic patients.

Drugs for peptic ulcer

Conservative management of peptic ulcer relies on the use of drugs as an adjuvant to the time-honored measures of avoiding stress, reducing gastric secretion, and regulating the diet. Alkalies neutralize acid and anticholinergic drugs partly inhibit secretion.. Both are widely used but are often inadequate to control symptoms. Carbenoxolone appears to have a more specific effect in promoting healing of gastric ulcers and has now been used for 15 years. Its role in the treatment of gastric ulcer can be critrically examined, particularly in relation to how this influences surgical management. Recently introduced compounds know as histamine H2-receptor antagonists have a profound effect in inhibiting gastric secretion. Early experience in patients with duodenal ulcer indicated the efficacy of these compounds in promoting healing. These potent new drugs are likely to influence strongly the management of patients with duodenal ulcer, and this may affect the indications for surgery.

Drug therapy of patients treated in hospitals for duodenal ulcers

Drug therapy in hospitalized patients treated for duodenal ulcer disease was reviewed retrospectively. The information was obtained by the means of a medical audit of patient records indexed by the discharge diagnosis of duodenal ulcers. A total of 485 cases were abstracted. Antacids were found to be the cornerstone of duodenal ulcer drug therapy. Anticholinergic drugs occupied a central role throughout the medical treatment of duodenal ulcers. The investigators identified a need for the dissemination of information concerning the use of anticholinergics in duodenal ulcer patients experiencing the complications of hemorrhage and obstruction.

Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Carbenoxolone sodium has been shown to accelerate the rate of healing of both gastric and duodenal ulcers, but its overall value in duodenal ulcer is probably less because of the high rate of natural remission of duodenal ulcers. Further studies are required to decide whether it should be used prophylactically to delay ulcer recurrence. Carbenoxolone may act by affecting both the proliferative activity of gastric epithelium and the differentiation of the epithelial cells to produce mucus (as well as favourably altering the physicochemical properties of mucus and by reducing peptic activity), factors which may be relevant ot the prevention of acute gastric ulcers. Some studies suggest that carbenoxolone adds to the effect of hospitalisation and bed rest on ulcer healing. Whether bed rest confers additional benefit to the drug's ulcer healing effect in outpatients is also uncertain. There is no evidence that accelerated healing by carbenoxolone is associated with improved overall prognosis. Carbenoxolone is of greatest benefit in accelerating the healing of gastric ulcers in patients for whom hospitalisation is not possible or desirable, but it should only be used in the ambulatory patient when careful and regular observation of serum electrolytes (particularly potassium), blood pressure and weight is possible and when it is known that the patient will attend regular follow-up. Patient must be educated in the proper use of the drug. If severe mineralocorticoid-like toxic effects such as sodium and water retention and hypokalaemia appear, as they do in a variable proportion of patients but most frequently in those receiving excessive doses, carbenoxolone should be stopped and the complication treated; they respond to thiazide diuretics and potassium supplements, and probably to amiloride given in conjunction with a low dose of a thiazide diuretic. Treatment with carbenoxolone can continue with concurrent diuretic therapy in patients with less severe side-effects. Optimum therapeutic effect in gastric ulcer with the least side-effects is achieved with a dosage of 100mg carbenoxolone tablets 3 times daily for the first week followed by 50mg 3 times daily thereafter, best taken before meals. A lower dosage is desirable in the elderly and in those with liver, cardiac or renal disease. Barium meal or preferably endoscopic examinations should be performed regularly and therapy continued until the ulcer is healed. Dosage for duodenal ulcer is 50mg 4 times daily, in special positioned-release capsules. These are best taken about 20 minutes before meals.

Promising ulcer drug runs into trouble

RETURN TO ISSUEPREVNewsNEXTPromising ulcer drug runs into troubleCite this: Chem. Eng. News 1974, 52, 35, 5Publication Date (Print):September 2, 1974Publication History Published online7 November 2010Published inissue 2 September 1974https://doi.org/10.1021/cen-v052n035.p005bCopyright © 1974 AMERICAN CHEMICAL SOCIETYArticle Views3Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (106 KB) SUBJECTS:Anatomy,Pharmaceuticals Get e-Alerts

The study on the effects of therapeutic drugs for peptic ulcer on tissue respiration and glycolysis of gastric mucosa.

The effects of various therapeutic drugs for ulcer on oxygen consumption and anaerobic glycolysis of the gastric mucosa and the ulcer tissue were investigated utilizing Warburg manometer, the oxygen consumption and the glycolysis were markedly promoted with 3 types of drugs, namely Calf Blood Ex., Gefarnate and Human Placenta Ex. Accordingly, it seems that the results mentioned above can be one of the guides for the clinical treatment of peptic ulcer.

11 - Evaluation of New Drugs for Peptic Ulcer

11 - Evaluation of New Drugs for Peptic Ulcer

Drugs for Gastric Ulcer

Drugs for Gastric Ulcer

Drugs for Gastric Ulcer

Drugs for Gastric Ulcer

STUDIES ON THE DRUGS FOR PEPTIC ULCER. A RELIABLE METHOD FOR PRODUCING STRESS ULCER IN RATS.

A simple and reliable method for production of gastric ulcer on rats by stress was described. Rats fixed on boards were immersed in water of 25°to the depth of xiphoide. After 20 hours, marked gastric erosions were found in the glandular portion of the stomach. This stress is more favourable than other stresses as cold, restraint, or emotional stress by stress box in view of incidence and mortality. Anticholinergics or central depressants effectively inhibited the ulceration and combination of both drugs suppressed it more effectively than single administration of each drug.

STUDIES ON THE DRUGS FOR PEPTIC ULCER. PHARMACOLOGICAL STUDIES ON THE EFFECTS OF SYNTHETIC ANTISPASMODICS MIXED WITH ANTACID.

STUDIES ON THE DRUGS FOR PEPTIC ULCER. PHARMACOLOGICAL STUDIES ON THE EFFECTS OF SYNTHETIC ANTISPASMODICS MIXED WITH ANTACID.

Anticholinergic Drugs for Peptic Ulcer

Anticholinergic Drugs for Peptic Ulcer